Stellenwert des Betablockers in der Hypertoniebehandlung – Rückbesinnung auf die individuelle Patientensituation

Die antihypertensive Therapie als solche reduziert das kardiovaskuläre Risiko. Die neuen Leitlinien der ESC geben 5 Klassen als antihypertensiv einsetzbare Medikamente an: Thiaziddiuretika, Calciumantagonisten, ACE-Hemmer, Angiotensin-1-Rezeptorantagonisten und Betablocker. Diese Medikamente können initial als Monotherapie oder in Kombination eingesetzt werden. Betablocker werden besonders bei jüngeren Patienten angewandt, während ältere Patienten eher von Diuretika profitieren. Sehr gut sind Betablocker kombinierbar mit Diuretika und Vasodilatatoren. Insgesamt erbringen Beta1-selektive Betablocker eine überzeugendere Risikoreduktion als nicht selektive. Neuere Betablocker der dritten Generation mit zusätzlich vasodilatierender Wirkkombination sind möglicherweise günstig, erfordern aber noch zusätzliche Studien. Betablocker sollten eingesetzt werden bei Patienten mit koronarer Herzerkrankung (Angina pectoris, Zustand nach Myokardinfarkt), Herzinsuffizienz, tachykarden Herzrhythmusstörungen/Tachyarrhythmie und sind exzellente Kombinationspartner mit Diuretika und Vasodilatatoren. Der Einsatz der Betablocker – wie eines jeden Antihypertensivums – sollte der individuellen Situation des Patienten Rechnung tragen. Bei den meisten unserer – oft multimorbiden – Patienten überwiegt der Vorteil einer Therapie mit Beta-Rezeptor-Antagonisten.

Antihypertensive treatment alone reduces the cardiovascular risk – the new ESC guidelines list 5 classes of drugs with antihypertensive properties: thiazide diuretics, calcium antagonists, ACE-inhibitors, angiotensin1 receptor antagonists and beta blockers. These drugs may be employed initially alone or in combination. Beta blockers are used in particular in younger patients, while older patients tend to profit more from diuretics. A very good option is a combination of beta blockers, diuretics and vasodilators. Overall, beta1 selective beta blockers have a greater risk-reducing effect than nonselective beta blockers. New third-generation beta blockers with an additional vasodilatory effect may prove favourable, but further studies are needed. Beta blockers should be employed in patients with coronary heart disease (angina pectoris, previous myocardial infarction), cardiac insufficiency, tachycardic arrhythmias/tachyarrhythmia and are excellent in combination with diuretics and vasodilators. As with any antihypertensive drug, the use of beta blockers should take account of the individual situation of the patient. In the majority of our – often multimorbid – patients the advantages predominate.

Beta blockers - hypertension - cardiovascular risk - monotherapy - combination treatment

Literatur

• 1 Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. . Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.  Lancet. 2003;  362 1527-1535
• 2 Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. . Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews and randomized trials.  Arch Int Med. 2005;  165 1410-1419
• 3 Brown MJ, Palmer CR, Castaigne A. et al. . Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).  Lancet. 2000;  356 366-372
• 4 Dahlöf B, Sever PS, Poulter NR. et al. . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.  Lancet. 2005;  366 895-906
• 5 Dahlöf B, Devereux RB, Kjeldsen SE. et al. . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 995-1003
• 6 DREAM Trial Investigators. . Effect of ramipril on the incidence of diabetes.  New Engl J Med. 2006;  355 1551-1562
• 7 Hansson L, Lindholm LH, Ekbom T. et al. . Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study.  Lancet. 1999;  354 1751-1756
• 8 Hansson L, Hedner T, Lund-Johansen P. et al. . Randomised trial of effects of calcium antagonists compared with diuretics and betablockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.  Lancet. 2000;  356 359-365
• 9 Heidenreich PA, McDonald KM, Hastie T. et al. . Meta-analysis of trials comparing betablockers, calcium antagonists, and nitrates for stable angina.  JAMA. 1999;  281 1927-1936
• 10 Hypertension: management of hypertension in adults in primary care. NICE/BHS. June 2006 www.nice,org.uk/CG 034
• 11 Lindholm LH, Carlberg B, Samuelsson O.. Should β blockers remain first choice in the treatment of primary hypertension?.  A meta-analysis.Lancet. 2005;  366 1545-1553
• 12 Lindholm LH, Ibsen H, Borch-Johnsen K. et al. . Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.  J Hypertens. 2002;  20 1879-1886
• 13 Mancia G, De Backer G, Dominiczak A. et al. . Guidelines for the Management of Arterial Hypertension.  J Hypertens. 2007;  25 1105-1187
• 14 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  JAMA. 2002;  288 2981-2997
• 15 Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.  BMJ. 1992;  304 405-412
• 16 Pott C, Steinritz D, Napp A, Bloch W, Schwinger RHG, Brixius K.. On the function of beta3-adrenoceptors in the human heart: signal transduction, inotropic effect and therapeutic prospects.  Wien Med Wochenschr. 2006;  156 451-458
• 17 Pott C, Brixius K, Bloch W, Ziskoven C, Napp A, Schwinger RHG.. ß3-adrenergic Stimulation in the Human Heart. Signal transduction, Functional Implications and Therapeutic Perspectives.  Die Pharmazie. 2005;  61 255-260
• 18 Reuter H, Grönke S, Schwinger RH.. Behandlung der Hypertonie bei Diabetes mellitus – was ist evidenzbasiert?. Diabetes, Stoffwechsel und Herz 2006: 6
• 19 SHEP Collaborative Research Group. . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP).  JAMA. 1991;  265 3255-3264
• 20 Staessen JA, Wang J, Thijs L.. Cardiovascular prevention and blood pressure reduction: a qualitative overview updated until 1 March 2003.  J Hypertens. 2003;  21 1055-1076
• 21 UK Prospective Diabetes Study Group. . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.  BMJ. 1998;  317 713-720
• 22 UK Prospective Diabetes Study Group. . Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 23 Mack C, Böhm M.. Klinischer Einsatz von β-Blockern bei kardiovaskulären Indikationen.  Pharm. unserer Zeit. 2004;  33 466-475

Korrespondenz